Project investment amounts expected to total
$5.4 million with Acenzia investing $600 thousand, Protein
Industries Canada investing $2.3 million, and two other partner
companies investing $2.5 million
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or
“Novo”) announced today that its wholly owned Canadian subsidiary,
Acenzia Inc. (“Acenzia”), has been selected by Protein Industries
Canada to participate in a new project to bring new protein
products with a superior nutritional amino acid profile to the
global marketplace. The total project is expected to see
approximately $5.4 million invested into the development,
reformulation, and commercialization of three consumer-ready
protein products: a modular, a ready-to-mix and a ready-to-drink
low-volume liquid protein. Acenzia will invest approximately
$600,000, Protein Industries Canada will invest approximately $2.3
million, and two other partner companies together will invest
approximately $2.5 million over three defined phases.
The project partners are utilizing innovative solutions to offer
alternative plant-based protein options that meet the quality,
sensory and muscle health benefits of whey protein isolate.
In addition to options that address medical nutrition needs,
including those associated with surgery, critical illness and
chronic disease, this project will also create products for the
active living and high-performance sports markets. The end products
will contain a novel plant-based protein ingredient blend with high
functionality and taste quality.
“Cultivating innovation and advancing health and wellness are at
the core of Acenzia's mission,” said Grant Bourdeau, co-founder and
President of Acenzia. “Acenzia has a longstanding history of
science-based product innovation and development of proprietary
technology which has been a key to our development and distribution
of effective health and wellness product solutions. As a proud
partner in this Protein Industries Canada-supported project, we are
excited to harness our expertise in contract manufacturing, product
formulation, R&D and sustainable packaging to develop
ecologically friendly, evidence-based, plant protein products that
cater to the evolving needs of consumers in the active living
market.”
About Acenzia Inc.
Acenzia’s 36,000 square foot facility is located in Windsor
Ontario Canada and includes Class 100 pharmaceutical grade
cleanrooms and certified laboratories from which Acenzia creates
and manufactures evidenced-based dietary, nutraceutical, and food
products that can be validated through personalized diagnostics.
Acenzia is dedicated to the creation of innovative therapeutics and
diagnostics that enables individualized health optimization.
Acenzia, founded in 2015, is licensed by multiple international
government agencies including Health Canada, the U.S. FDA and the
European Union for Good Manufacturing Practices (GMP) for
over-the-counter and dietary supplement manufacturing. In addition,
Acenzia maintains multiple third-party licenses including from the
National Sanitation Foundation International (NSF) for meeting the
required public health standards for manufacturing food, nutrition,
and supplements.
For more information, please visit www.acenzia.com.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of services and product innovation. Novo
offers an essential and differentiated solution to deliver, or
intend to deliver, these services and products through the
integration of medical technology, advanced therapeutics, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered both
now and in the future. Specific to non-critical care, ongoing
advancements in both medical technology and inter-connectivity are
allowing for a shift of the patient/practitioner relationship to
the patient’s home and away from on-site visits to primary medical
centers with mass-services. This acceleration of “ease-of-access”
in the patient/practitioner interaction for non-critical care
diagnosis and subsequent treatment minimizes the degradation of
non-critical health conditions to critical conditions as well as
allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner thus expanding the reach and
availability of the Company’s services, beyond the traditional
clinic location, to geographic areas not readily providing
advanced, peripheral based healthcare services, including the
patient’s home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions allowing for the
customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to
product innovation further emphasizes our mandate to create and
provide over-the-counter preventative and maintenance care
solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting-edge advancement in patient-first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com.
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, or the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical facts included
in this press release are forward-looking statements. In some
cases, forward-looking statements can be identified by words such
as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue," or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks, and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240605676404/en/
Chris David, COO Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Novo Integrated Sciences (NASDAQ:NVOS)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
